-
2 months ago | 
jdsupra.com | Michele Gipp |David Greenberg |Douglas Grimm
With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year. 1. The Trump Takeover: New Administration, New Congress, and New Priorities Impacting Health Care SectorSince President Trump’s inauguration, we have seen a flurry of presidential executive orders impacting the health care sector.
-
2 months ago | 
afslaw.com | David Greenberg |Douglas Grimm |Annie Lee |Michele Gipp
On 1. The Trump Takeover: New Administration, New Congress, and New Priorities Impacting Health Care SectorSince President Trump’s inauguration, we have seen a flurry of presidential executive orders impacting the health care sector.
-
Oct 3, 2024 | 
afslaw.com | Douglas Grimm
Health care industry leaders are attempting to keep up with technological advancements by incorporating AI into their organizations; however, federal regulations have yet to provide rules for compliance. Douglas told Law360 that there are very few legal questions among the concerns clients bring up around Al in health care because the regulations don’t exist yet.
-
Sep 12, 2024 | 
afslaw.com | Douglas Grimm
Date & Time - Location Online Event Type Webinar Add to Calendar Disabled Health Care Practice Leader Douglas Grimm co-led a September 12, 2024, Strafford CLE webinar for health care practitioners on the recent notable US Supreme Court decisions in Loper Bright Enterprises v. Raimondo and Corner Post v. Board of Governors of the Federal Reserve System.
-
Sep 4, 2024 | 
jdsupra.com | Shoshana Golden |Douglas Grimm |Gayland Hethcoat II
In 2021, we provided an overview of multiple federal lawsuits challenging the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) enforcement of the 340B Drug Pricing Program, particularly with respect to contract pharmacies. Three years later, the “340B Saga” continues. Following the filing of new cases and developments in others, we are back with another update.
-
Sep 3, 2024 | 
natlawreview.com | Douglas Grimm
In 2021, we provided an overview of multiple federal lawsuits challenging the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) enforcement of the 340B Drug Pricing Program, particularly with respect to contract pharmacies. Three years later, the “340B Saga” continues. Following the filing of new cases and developments in others, we are back with another update.
-
Sep 3, 2024 | 
afslaw.com | Douglas Grimm |Stephanie Trunk |Shoshana Golden
On Drug Manufacturers Prevail on Appeal in Challenges to HRSA’s Efforts to Limit Contract Pharmacy ConditionsThe 340B Program provides certain health care organizations, referred to as “covered entities,” with access to discounted outpatient drugs from manufacturers. Many covered entities, lacking their own pharmacies, enter into agreements with outside pharmacies, or “contract pharmacies,” to dispense discounted drugs to patients.
-
Jul 26, 2024 | 
afslaw.com | Douglas Grimm
The rise in state laws is partly in response to more than two dozen pharmaceutical manufacturers restricting 340B discounts on prescriptions filled by contract pharmacies. The drugmakers limited the discounts after winning several lawsuits challenging the federal government’s authority to compel discounted drugs. “The contract pharmacy issue is just one of many heavily litigated areas of the 340B program,” Douglas said.
-
Jul 26, 2024 | 
afslaw.com | Douglas Grimm
After a preliminary injunction was struck down, the FTC quickly filed an appeal, which means the agency is likely to keep pushing the case, Douglas said. “You can infer that pretty reasonably, I think, from the speed with which they appealed and the depth and breadth of their appeal,” he said.
-
Jul 15, 2024 | 
jdsupra.com | Lowell Brown |David Greenberg |Douglas Grimm
On June 28, the US Supreme Court overturned the Chevron doctrine — the legal principle that the judiciary should defer to a federal agency’s reasonable interpretation of an ambiguous statute. Chevron reflected the view that a federal agency’s subject matter experts are best positioned to interpret and set policy when the language of a statute is silent or ambiguous regarding a specific issue, as opposed to a judge with little experience in the subject matter area.
